For instance, Olaparib resistance was conferred in BRCA2-deficient cancers harboring frame-shift mutations through subsequent mutations that restored the BRCA2 reading frame to effectively/partially rescue the HRR defect [47]. Here, BRCA2 is linked to cancer.